REACH Registration in 2025: Dossier Quality, Substance Identity, and Exposure Data Challenges
In 2024, ECHA issued more than 200 formal decisions asking companies to provide new information—often on long-term human health and environmental endpoints. Around 30% of these cases are now in enforcement hands, underlining a pattern: dossiers are not keeping pace with regulatory expectations. This is not about “old” dossiers anymore—every submission is under scrutiny. Substance […]
Why Managing EU REACH Compliance Is Complex for Non-EU Producers – And How Agile EU Partners Can Help
The European Union’s REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) regulation is one of the strictest chemical regulatory frameworks in the world. For non-EU producers — companies outside the European Economic Area (EEA) or Northern Ireland — navigating REACH is a significant challenge, but a necessary one for accessing the lucrative EU market. Why […]
Endocrine Disruptor Assessment Under CLP: Key Challenges and How We Delivered a Robust, Regulator-Ready Outcome
Under CLP Delegated Regulation (EU) 2023/707, companies must assess whether substances meet criteria for endocrine disruption in humans (ED HH) or the environment (ED ENV). This post outlines how RegSurance conducted a full ED assessment for a high-volume industrial chemical using a transparent weight-of-evidence approach aligned with EFSA–ECHA Guidance 2018, resulting in a defensible, non-classification […]